Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N E Lepor

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Reviews in Cardiovascular Medicine|January 2, 2003
Radiocontrast nephropathy: managing the high-risk patient. IntroductionN E Lepor
Reviews in Cardiovascular Medicine|November 29, 2002
Radiocontrast nephropathy: the dye is not castN E Lepor
Reviews in Cardiovascular Medicine|November 20, 2002
Summary of the third report of the National Cholesterol Education Program Adult Treatment Panel IIIN E Lepor, R E Vogel,
Reviews in Cardiovascular Medicine|November 29, 2002
Anorexigen-related cardiopulmonary toxicityS B Gross, N E Lepor
Clinical Cardiology|August 1, 1989
Does nitroglycerin induce heparin resistance?N E Lepor, D K Amin, L Berberian, et al.
The American Journal of Cardiology|March 12, 1999
Intravascular ultrasound imaging of ruptured atherosclerotic plaques in coronary arteriesT Nagai, H Luo, S Atar, et al.
Reviews in Cardiovascular Medicine|November 20, 2002
Design and rationale of CONTRAST--a prospective, randomized, placebo-controlled trial of fenoldopam mesylate for the prevention of radiocontrast nephropathyG W Stone, J A Tumlin, H Madyoon, et al.
The American Journal of Cardiology|June 27, 2000
Dose and duration of fenfluramine-phentermine therapy impacts the risk of significant valvular heart diseaseN E Lepor, S B Gross, W L Daley, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Reviews in Cardiovascular Medicine|January 2, 2003
Radiocontrast nephropathy: managing the high-risk patient. IntroductionN E Lepor
Reviews in Cardiovascular Medicine|November 29, 2002
Radiocontrast nephropathy: the dye is not castN E Lepor
Reviews in Cardiovascular Medicine|November 20, 2002
Summary of the third report of the National Cholesterol Education Program Adult Treatment Panel IIIN E Lepor, R E Vogel,
Reviews in Cardiovascular Medicine|November 29, 2002
Anorexigen-related cardiopulmonary toxicityS B Gross, N E Lepor
Clinical Cardiology|August 1, 1989
Does nitroglycerin induce heparin resistance?N E Lepor, D K Amin, L Berberian, et al.
The American Journal of Cardiology|March 12, 1999
Intravascular ultrasound imaging of ruptured atherosclerotic plaques in coronary arteriesT Nagai, H Luo, S Atar, et al.
Reviews in Cardiovascular Medicine|November 20, 2002
Design and rationale of CONTRAST--a prospective, randomized, placebo-controlled trial of fenoldopam mesylate for the prevention of radiocontrast nephropathyG W Stone, J A Tumlin, H Madyoon, et al.
The American Journal of Cardiology|June 27, 2000
Dose and duration of fenfluramine-phentermine therapy impacts the risk of significant valvular heart diseaseN E Lepor, S B Gross, W L Daley, et al.
Pageof 1